RDY
Income statement / Annual
Last year (2024), Dr. Reddy's Laboratories Limited's total revenue was $279.16 B,
an increase of 13.54% from the previous year.
In 2024, Dr. Reddy's Laboratories Limited's net income was $55.68 B.
See Dr. Reddy's Laboratories Limited’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
03/31/2024 |
03/31/2023 |
03/31/2022 |
03/31/2021 |
03/31/2020 |
03/31/2019 |
03/31/2018 |
03/31/2017 |
03/31/2016 |
03/31/2015 |
| Operating Revenue |
$279.16 B
|
$245.88 B
|
$214.39 B
|
$189.72 B
|
$174.60 B
|
$153.85 B
|
$142.03 B
|
$140.81 B
|
$154.71 B
|
$148.19 B
|
| Cost of Revenue |
$115.56 B |
$42.91 B |
$100.55 B |
$86.65 B |
$80.59 B |
$70.42 B |
$65.72 B |
$62.45 B |
$62.43 B |
$62.79 B |
| Gross Profit |
$163.61 B |
$202.97 B |
$113.84 B |
$103.08 B |
$94.01 B |
$83.43 B |
$76.30 B |
$78.36 B |
$92.28 B |
$85.40 B |
| Gross Profit Ratio |
0.59 |
0.83 |
0.53 |
0.54 |
0.54 |
0.54 |
0.54 |
0.56 |
0.6 |
0.58 |
| Research and Development
Expenses |
$22.87 B
|
$19.38 B
|
$17.48 B
|
$16.54 B
|
$15.41 B
|
$15.61 B
|
$18.27 B
|
$19.55 B
|
$17.83 B
|
$17.45 B
|
| General & Administrative
Expenses |
$0.00
|
$46.47 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$59.47 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$77.20 B
|
$105.93 B
|
$62.08 B
|
$54.56 B
|
$50.13 B
|
$48.89 B
|
$46.91 B
|
$46.37 B
|
$45.70 B
|
$42.59 B
|
| Other Expenses |
-$4.20 B |
-$7.70 B |
-$2.76 B |
-$982.00 M |
-$4.29 B |
-$691.00 M |
-$843.00 M |
-$1.15 B |
-$986.00 M |
-$1.06 B |
| Operating Expenses |
$95.88 B |
$117.62 B |
$76.80 B |
$70.12 B |
$61.25 B |
$62.54 B |
$64.39 B |
$64.86 B |
$62.66 B |
$59.12 B |
| Cost And Expenses |
$211.44 B |
$160.52 B |
$177.35 B |
$156.76 B |
$141.84 B |
$132.96 B |
$130.11 B |
$127.31 B |
$125.09 B |
$121.90 B |
| Interest Income |
$2.28 B |
$1.18 B |
$3.08 B |
$2.62 B |
$888.00 M |
$2.28 B |
$540.00 M |
$558.00 M |
$1.40 B |
$1.06 B |
| Interest Expense |
$1.71 B |
$1.43 B |
$958.00 M |
$970.00 M |
$983.00 M |
$1.16 B |
$788.00 M |
$634.00 M |
$826.00 M |
$1.09 B |
| Depreciation &
Amortization |
$14.84 B
|
$12.64 B
|
$11.82 B
|
$12.80 B
|
$12.47 B
|
$12.19 B
|
$11.71 B
|
$11.28 B
|
$10.25 B
|
$8.10 B
|
| EBITDA |
$82.57 B
|
$74.43 B
|
$47.74 B
|
$45.71 B
|
$41.79 B
|
$31.87 B
|
$23.74 B
|
$24.55 B
|
$40.18 B
|
$35.16 B
|
| EBITDA Ratio |
0.3 |
0.44 |
0.25 |
0.26 |
0.28 |
0.15 |
0.08 |
0.1 |
0.19 |
0.18 |
| Operating Income Ratio
|
0.24
|
0.39
|
0.19
|
0.19
|
0.21
|
0.14
|
0.08
|
0.1
|
0.19
|
0.18
|
| Total Other
Income/Expenses Net |
$4.14 B
|
$3.34 B
|
$2.82 B
|
$4.04 B
|
$2.04 B
|
$1.56 B
|
$2.42 B
|
$1.16 B
|
-$2.48 B
|
$1.88 B
|
| Income Before Tax |
$71.87 B |
$60.49 B |
$32.30 B |
$28.32 B |
$18.03 B |
$22.44 B |
$14.34 B |
$14.65 B |
$27.14 B |
$28.16 B |
| Income Before Tax Ratio
|
0.26
|
0.25
|
0.15
|
0.15
|
0.1
|
0.15
|
0.1
|
0.1
|
0.18
|
0.19
|
| Income Tax Expense |
$16.19 B |
$15.41 B |
$8.73 B |
$9.18 B |
-$1.47 B |
$3.65 B |
$4.54 B |
$2.61 B |
$7.13 B |
$5.98 B |
| Net Income |
$55.68 B |
$45.07 B |
$23.57 B |
$17.24 B |
$19.50 B |
$18.80 B |
$9.81 B |
$12.04 B |
$20.01 B |
$22.18 B |
| Net Income Ratio |
0.2 |
0.18 |
0.11 |
0.09 |
0.11 |
0.12 |
0.07 |
0.09 |
0.13 |
0.15 |
| EPS |
334.02 |
271.47 |
142.08 |
103.94 |
117.62 |
113.28 |
59.13 |
72.24 |
117.34 |
130.22 |
| EPS Diluted |
334.02 |
270.9 |
141.69 |
103.65 |
117.4 |
113.09 |
59.01 |
72.09 |
116.98 |
129.75 |
| Weighted Average Shares
Out |
$166.71 M
|
$166.03 M
|
$165.88 M
|
$165.84 M
|
$165.76 M
|
$165.92 M
|
$165.85 M
|
$166.65 M
|
$170.55 M
|
$170.31 M
|
| Weighted Average Shares
Out Diluted |
$166.71 M
|
$166.38 M
|
$166.34 M
|
$166.32 M
|
$166.08 M
|
$166.20 M
|
$166.19 M
|
$167.00 M
|
$171.07 M
|
$170.93 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
